News
KDNY
24.82
+0.24%
0.06
SVB Securities Reaffirms Their Buy Rating on Chinook Therapeutics (KDNY)
TipRanks · 01/16 05:05
Vera: Disappointing Data From Phase 2 ORIGIN Trial, Initiating Coverage With A Sell Rating
Seeking Alpha · 01/12 16:34
Chinook Therapeutics: Best Biotech For Kidney Disease Exposure, With Catalysts
Seeking Alpha · 01/06 17:21
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Pfizer (PFE), Chinook Therapeutics (KDNY) and Zymeworks (ZYME)
TipRanks · 01/06 05:20
Vera Therapeutics downgraded to neutral at Wedbush following atacicept data setback
Seeking Alpha · 01/04 22:50
Have A Look At William Blair's Top Biotech Picks For 2023
Benzinga · 12/25/2022 18:32
Chinook Therapeutics's Return On Capital Employed Insights
Benzinga · 12/22/2022 14:47
Stifel Maintains Buy on Chinook Therapeutics, Raises Price Target to $43
Benzinga · 12/22/2022 12:10
Stifel Raises Price Target on Chinook Therapeutics to $43 From $30, Keeps Buy Rating
Stifel Raises Price Target on Chinook Therapeutics to $43 From $30, Keeps Buy Rating
MT Newswires · 12/22/2022 08:01
Insider Sell: Chinook Therapeutics
Insider Sell: Chinook Therapeutics
MT Newswires · 12/15/2022 16:42
Wells Fargo Initiates Coverage On Chinook Therapeutics with Overweight Rating, Announces Price Target of $30
Benzinga · 12/05/2022 12:33
Wells Fargo Starts Chinook Therapeutics at Overweight With $30 Price Target
Wells Fargo Starts Chinook Therapeutics at Overweight With $30 Price Target
MT Newswires · 12/05/2022 08:28
Chinook Therapeutics to Present at Upcoming Investor Conferences
SEATTLE, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook managemen...
GlobeNewswire · 11/22/2022 21:05
BRIEF-Chinook Therapeutics Inc Files Prospectus Supplement For Potential Offering Of Up To $150 Million Of Common Stock
Reuters · 11/10/2022 22:26
Chinook Therapeutics GAAP EPS of -$0.83 misses by $0.20, revenue of $2.5M beats by $2.38M
Seekingalpha · 11/10/2022 22:14
Chinook Therapeutics Q3 EPS $(0.83) Down From $(0.69) YoY
Benzinga · 11/10/2022 21:25
BRIEF-Chinook Therapeutics Inc Reports Q3 EPS Of $0.83
Reuters · 11/10/2022 21:03
Chinook Therapeutics Q3 Loss Widens, Revenue Rises
Chinook Therapeutics Q3 Loss Widens, Revenue Rises
MT Newswires · 11/10/2022 16:25
More
Webull provides a variety of real-time KDNY stock news. You can receive the latest news about Chinook Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About KDNY
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing medicines for kidney diseases. Its lead product candidate is atrasentan, which is a selective endothelin A receptor antagonist that is developed for the treatment of proteinuric glomerular diseases. The Company’s second product candidate, BION-1301, is an investigational humanized IgG4 monoclonal antibody that blocks APRIL, a soluble factor that is implicated in IgAN and other indications, from binding to its receptors. Its third clinical development candidate is CHK-336, a liver-targeted oral small molecule lactate dehydrogenase (LDHA), inhibitor, which is developed for the treatment of primary hyperoxaluria (PH), as well as secondary hyperoxaluria and idiopathic kidney stone formation. It is conducting a Phase I/II clinical trial of BION-1301.